Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Editor
New York, USA
23+ years of experience
Scrip
By Jessica Merrill 04 May 2021
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.
Scrip
By Jessica Merrill 20 Apr 2021
J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.
Scrip
By Jessica Merrill 28 Jan 2021
Joined by Datamonitor Healthcare analyst Derek Burkhard, Scrip editors discuss the pharma landscape coming out of 2020 and where industry stands heading into 2021.
Scrip
By Jessica Merrill 27 Nov 2020
The company – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.
Topic Coronavirus Vaccines
Scrip
By Jessica Merrill 19 Oct 2020
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.
Scrip
By Jessica Merrill 30 Jul 2020
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Scrip
By Jessica Merrill 01 Jun 2020
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.
Topic Coronavirus
Scrip
By Jessica Merrill 08 Jan 2020
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
Topic Deals Leadership M A
Scrip
By Jessica Merrill 28 Nov 2019
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
Scrip
By Jessica Merrill 06 Nov 2019
Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.
Scrip
By Jessica Merrill 14 Aug 2019
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.
Scrip
By Jessica Merrill 02 Jul 2019
The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.
Scrip
By Jessica Merrill 02 Jul 2019
CEO Craig Wheeler talked toScripabout the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.
Scrip
By Jessica Merrill 02 Jul 2019
PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads.
Topic Approvals Drug Review
Scrip
By Jessica Merrill 28 May 2019
J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.
Topic Policy & Regulation
Medtech Insight
22 Jul 2022
Scrip
19 Jul 2022
Scrip
18 Jul 2022
Scrip
07 Jul 2022
Scrip
05 Jul 2022
Scrip
04 Jul 2022
Scrip
23 Jun 2022
Scrip
21 Jun 2022
Scrip
09 Jun 2022
Scrip
03 Jun 2022
Scrip
31 May 2022
Scrip
19 May 2022
Scrip
16 May 2022
Scrip
09 May 2022
Scrip
05 May 2022
